bluebird navigating cash crunch as PDUFA dates approach

Bluebird’s honeymoon period after splitting into two companies ended abruptly Friday, with Gina Consylman resigning as CFO and the company revealing it has a year of cash left and needs to explore financing opportunities to stay afloat, such as selling any priority review vouchers it receives.

Shares of bluebird bio Inc. (NASDAQ:BLUE) have fallen 68% since Oct. 19, when it split into two independent, publicly traded companies. After grappling with safety setbacks for its gene therapies last year and closing up shop in Europe, the company regrouped on its home turf, where it has been looking ahead to a “landmark” year with two PDUFA dates for rare disease programs. ...